Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of anti-TNFα efficacy in ankylosing spondylitis
2013-004406-25Phase 4Completed
- Sponsor
- NOVA Medical School
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of adalimumab in ankylosing spondylitis (AS), sponsored by NOVA Medical School. Primary endpoints: Differential gene expression biomarkers of anti-TNFα response and Proteomic biomarkers of anti-TNFα response. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2013-004406-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004406-25.